Alexander eggermont biography
- Professor Eggermont is a.
- Professor Eggermont is a melanoma specialist and immunotherapy development specialist.
- Born in Amsterdam in 1952, the son of two language teachers, Eggermont distinguished himself at school, achieving a top school baccalaureate.
- •
About Us
Special Interview with Professor Alexander Eggermont - Director General of Gustave Roussy Comprehensive Cancer Center
“AMC has excellent medical professionals and research infrastructure and needs to converge basic and clinical researches.”
Professor Alexander Eggermont is Full Professor of Oncology at the Paris-Sud University, Full Professor of Surgical Oncology as well as Endowed Professor of International Networking in Cancer Research at the Erasmus University Medical Center, the Director General of Gustave Roussy Comprehensive Cancer Center, the president of the European Academy of Cancer Sciences, and the Vice-President of WIN-Global Consortium for Personalized Cancer Medicine.
Professor Alexander Eggermont, the Director General of Gustave Roussy Comprehensive Cancer Center, visited AMC to attend the symposium host by AMC Cancer Institute. The Cancer Institute a symposium under the theme ‘From the Basic of Multidisciplinary Management to the Cutting-edge of the Personalized Medicine’ on August 29 and
- •
An interview with Alexander Eggermont
Taking a “helicopter view of oncology” has become the main role of Alexander Eggermont, the first president of the newly reformed European CanCer Organisation (ECCO), who is the driving force behind a new initiative to provide European governments with a “rationale” voice on oncology.
But Eggermont, as head of the department of Surgical Oncology at the Erasmus University Medical Centre, who also holds a Chair of Experimental Surgical Oncology endowed by the Dutch Cancer Society, has done his fair share at the coal face of scientific endeavour. His multiple scientific achievements include helping to establish a TNF based isolated limb perfusion program in Europe, a significant contribution to drug development and clinical trial methodology, particularly in the fields of melanoma and sarcoma, and the establishment of a world class laboratory in tumour patho physiology. Eggermont's prodigious publication output includes 500 peer reviewed publications, book chapters and monographs.
Professor Eggermont, “Lex” to his friends, is a firm believer
- •
Alexander Eggermont – General Director, Gustave Roussy, France
Professor Alexander Eggermont, general director of Gustave Roussy, gives insights into the transformation of the Hospital under his ten-year leadership mandate. He also explains the rationale behind creating Cancer Core Europe, a collaborative platform of Europe’s seven leading cancer institutes.
What have been your priorities since we last interviewed you, four years ago?
My main objective has been the continuation of transforming Gustave Roussy from a comprehensive cancer centre to the comprehensive cancer centre dedicated to innovation. In that context, we have created a new drug development entity called the Department of Therapeutic Innovation and Early Trials (DITEP), which is the only division of its kind in Europe. It is a fully-fledged department with more than 200 people working on 125 early clinical trials, 67 of which are in the area of immuno-therapy. When I arrived here back in 2010, we only had one Phase I immuno-therapy clinical trial, so I am quite proud of this achievement.
The transfo
Copyright ©dadtori.pages.dev 2025